

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

APOTEX INC. and APOTEX CORP.,  
Petitioner,

v.

ALCON RESEARCH, LTD.,  
Patent Owner.

---

Case IPR2016-01640  
Patent 8,791,154 B2

---

Before JENNIFER MEYER CHAGNON, CHRISTOPHER M. KAISER,  
and CHRISTOPHER G. PAULRAJ, *Administrative Patent Judges*.

KAISER, *Administrative Patent Judge*.

DECISION  
Institution of *Inter Partes* Review  
*37 C.F.R. § 42.108*

## INTRODUCTION

### *A. Background*

Apotex Inc. and Apotex Corp. (“Petitioner”) filed a Petition (Paper 2, “Pet.”) requesting *inter partes* review of claims 1–4, 8, 12, 13, 21, and 22 of U.S. Patent No. 8,791,154 B2 (Ex. 1001, “the ’154 patent”). Alcon Research, Ltd. (“Patent Owner”) waived its opportunity to file a Preliminary Response. Paper 7, 2. Petitioner also moved for joinder with IPR2016-00544, an ongoing *inter partes* review that we instituted on July 18, 2016. Paper 3. Patent Owner does not oppose the motion for joinder. Paper 7, 2.

We have authority to determine whether to institute an *inter partes* review. 35 U.S.C. § 314(b); 37 C.F.R. § 42.4(a). The standard for instituting an *inter partes* review is set forth in 35 U.S.C. § 314(a), which provides that an *inter partes* review may not be instituted unless “there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.” Petitioner may be joined as a party to a previously instituted *inter partes* review if Petitioner “properly files a petition . . . that [we] . . . determine[] warrants the institution of an *inter partes* review.” 35 U.S.C. § 315(c); 37 C.F.R. § 42.4(a).

After considering the Petition and the evidence currently of record, we determine that Petitioner has demonstrated that there is a reasonable likelihood that it would prevail with respect to at least one of the claims challenged in the Petition. Accordingly, we institute *inter partes* review. Because Petitioner has filed a Petition that warrants institution, we join Petitioner as a party to IPR2016-00544, and we terminate the present proceeding.

*B. Related Matters*

The parties note that the '154 patent is the subject of *Alcon Research, Ltd. v. Watson Laboratories, Inc.*, Case No. 1-15-cv-01159-SLR (D. Del.), as well as *Alcon Research, Ltd. v. Lupin Ltd.*, Case No. 1-16-cv-00195 (D. Del.). Pet. 1–2; Paper 6, 2.

*C. The Asserted Grounds of Unpatentability*

Petitioner contends that claims 1–4, 8, 12, 13, 21, and 22 of the '154 patent are unpatentable based on the following grounds (Pet. 18–59):<sup>1</sup>

<b>Statutory Ground</b>	<b>Basis</b>	<b>Challenged Claims</b>
§ 103	Bhowmick, <sup>2</sup> Yanni, <sup>3</sup> and Castillo <sup>4</sup>	1–4, 8, 12, 13, 21, and 22
§ 103	Schneider, <sup>5</sup> Hayakawa, <sup>6</sup> Bhowmick, and Castillo	1–4, 8, 12, 13, 21, and 22

---

<sup>1</sup> Petitioner also relies on declarations from Erning Xia, Ph.D. (Ex. 1002) and Leonard Bielory, M.D (Ex. 1003).

<sup>2</sup> Bhowmick et al., WO 2008/015695 A2, published Feb. 7, 2008 (Ex. 1004, “Bhowmick”).

<sup>3</sup> J.M. Yanni et al., *The In Vitro and In Vivo Ocular Pharmacology of Olopatadine (AL-4943A), an Effective Anti-Allergic/Antihistaminic Agent*, 12 J. OCULAR PHARMACOLOGY & THERAPEUTICS 389, 389–400 (1996) (Ex. 1005, “Yanni”).

<sup>4</sup> Castillo et al., U.S. Patent No. 6,995,186 B2, issued Feb. 7, 2006 (Ex. 1006, “Castillo”).

<sup>5</sup> Schneider et al., US 2011/0082145 A1, published Apr. 7, 2011 (Ex. 1007, “Schneider”).

<sup>6</sup> Hayakawa et al., U.S. Patent No. 5,641,805, issued June 24, 1997 (Ex. 1008, “Hayakawa”).

These are identical to the grounds of unpatentability asserted in IPR2016-00544.

*D. The '154 Patent*

The '154 patent relates to “an ophthalmic composition containing a relatively high concentration of olopatadine.” Ex. 1001, at [57]. This “invention is directed to an ophthalmic composition for treatment of allergic conjunctivitis.” *Id.* at 2:41–42. The '154 patent describes the claimed compositions as including “at least 0.67 w/v % olopatadine, preferably dissolved in solution.” *Id.* at 2:42–45. The claimed compositions also are described as “typically includ[ing] a cyclodextrin, and more particularly, a  $\gamma$ -cyclodextrin derivative and/or a  $\beta$ -cyclodextrin derivative to aid in solubilizing the olopatadine.” *Id.* at 2:45–48. In addition, the '154 patent describes other ingredients to assist in solubilization of the olopatadine, including “a lactam polymer (e.g., polyvinylpyrrolidone (PVP))” and “a polyether (e.g., polyethylene glycol (PEG)).” *Id.* at 2:52–57. The claimed compositions also are described as including “a preservative” such as “benzalkonium chloride,” as well as “borate and/or polyol to aid in achieving desired preservation.” *Id.* at 2:60–67. In addition to the claimed compositions, the '154 patent also describes “a method of treating ocular allergy symptoms” by “topically applying [the claimed compositions] to an eye of a human,” preferably by “dispensing an eyedrop from an eyedropper.” *Id.* at 3:1–6.

*E. Illustrative Claims*

Of the challenged claims in the '154 patent, claims 1, 4, 8, and 21 are independent. Ex. 1001, 26:28–28:13. Independent claims 1 and 4 and dependent claim 12 are illustrative. They recite:

1. An aqueous ophthalmic solution for treatment of ocular allergic conjunctivitis, the solution comprising:
  - at least 0.67 w/v % olopatadine dissolved in the solution;
  - PEG having a molecular weight of 300 to 500;
  - polyvinylpyrrolidone;
  - hydroxypropyl- $\gamma$ -cyclodextrin;
  - benzalkonium chloride; and
  - water.

Ex. 1001, 26:28–35.

4. An aqueous ophthalmic solution for treatment of ocular allergic conjunctivitis, the solution comprising:
  - at least 0.67 w/v % but no greater than 1.0 w/v % olopatadine dissolved in the solution;
  - 2.0 w/v % to 6.0 w/v % PEG having a molecular weight of 300 to 500;
  - 2.0 w/v % to 6.0 w/v % polyvinylpyrrolidone;
  - at least 0.5 w/v % but no greater than 2.0 w/v % cyclodextrin derivative selected from the group consisting of SAE- $\beta$ -cyclodextrin, HP- $\gamma$ -cyclodextrin, HP- $\beta$ -cyclodextrin and combinations thereof; and
  - water.

Ex. 1001, 26:39–50.

12. A method of treating at least one ocular allergy symptom in humans, the method comprising:
  - topically applying to an eye of a human an amount of the solution of claim 4 sufficient to treat the at least one ocular allergy symptom.

Ex. 1001, 27:7–11.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.